5 Papers
Lin Zhou is an academic researcher from Shanghai Aircraft Design and Research Institute. The author has contributed to research in topics: Medicine & Internal medicine. The author has co-authored 1 publications.
Chat about Author
Papers
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
Xu Yang,Bowen Chen,Yanyu Wang,Yunchao Wang,Junyu Long,Na Zhang,Jing Xue,Ziyu Xun,Lin-Zhi Zhang,Jiamin Cheng,Jin Lei,Huishan Sun,Yiran Li,Jianzhen Lin,Fucun Xie,Dongxu Wang,Jie Pan,Ke-Xing Hu,M. Guan,Li Huo,Jie Shi,Ling-xiang Yu,Lin Zhou,Jin-Rhong Zhou,Zhenhui Lu,Xiaobo Yang,Yilei Mao,Xinting Sang,Yinying Lu,Haitao Zhao +29 more
TL;DR: Wang et al. as mentioned in this paper investigated the real-world efficacy of and prognostic factors for survival associated with lenvatinib plus PD-1 inhibitor treatment in a large cohort of Asian uHCC patients even the global LEAP-002 study failed to achieve the primary endpoints.
Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
Bowen Chen,Jin Lei,Haitao Zhao,Jinghui Dong,Zhen Zeng,Yinying Lu,Ling-xiang Yu,Lin Zhou,Aiying Jia,Jiamin Cheng +9 more
TL;DR: In this article , the efficacy and safety of sorafenib- or lenvatinib-based combination therapy with PD-1 inhibitors in elderly patients aged ≥75 years with unresectable hepatocellular carcinoma (uHCC) were continually reviewed.
3
Evaluation Method and Standard on Maintainability of Cockpit
Junwei Zhao,Lin Zhou,Haitao Zhao,Xuming Mao,Youchao Sun +4 more
- 01 Jan 2011
TL;DR: This article takes control column and side stick with related standards as an example and establishes evaluation method, and contrasts and analyzes the related cockpit parameters of A320 and B737.
Efficacy and safety in unresectable hepatocellular carcinoma using atezolizumab plus bevacizumab in later-line: A retrospective analysis of real-world evidence.
Jiamin Cheng,Bowen Chen,Xinfeng Zhang,Guodong Su,Caiyun Peng,Lin Zhou,Jin Lei,Yinying Lu +7 more
TL;DR: In this article , later-line regorafenib plus bevacizumab (T+A) was used to treat patients with hepatocellular carcinoma (uHCC).
Patients with uHCC and Child-Pugh B8/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study.
Xiaoyan Ding,Xue Yin,Linlin Zheng,Lin Zhou,Junke Hu,Lei Sun,Yanjun Shen,Ying Teng,Yawen Xu,Wendong Li,Mei Liu,Jinglong Chen +11 more